Teckro, a software platform that claims to make the conduct of clinical trials more efficient and collaborative, has closed $ 25 million in Series C funding. The round, which brings $ 43 million, is led Northpond Ventures with participation from Founder's Fund, Sands Capital Ventures, Bill Maris' Section 32 Venture Fund, and Borealis Ventures.
Founded by brothers Gary and Nigel Hughes, and Jacek Skrzypiec in 2015, Teckro's technology is designed to improve the conduct of clinical trials, including by learning machine to improve the speed and accuracy of clinical trials. Through Digitization, 1965, pp. 1963-002 "The industry still relies heavily on paper, on working off retrospective data, and there." is silent on over-reliance on sending CRAs to busy research sites, "says Teckro co-founder and CEO Gary Hughes.
To that end, Teckro says it has users in over 80 countries, "This approach, together with the plethora of point solutions that get 'bolted on', only adds to the complexity and disjointed experience of research sites and patients". It's over 1
"Hughes tells me. Physicians (currently less than 3 percent globally) want to provide greater access to patients, effectively making clinical research a treatment option for millions of patients with unmet medical needs. That requires a complete rethink of clinical trial operations, especially the experience of research sites.
The broader Teckro vision is to be "at The center of all site and patient interactions in a clinical trial, says Hughes.
The resulting aim is to reduce the risk of damage to drugs to the patient "so that [more] lives can be saved".